reports
Diabetes Roundup III - $6500
Read the details on Diabetes Round Up III here
Diabetes Roundup II - $2500
Read our eight page introduction to Diabetes Round Up II here
Diabetes Roundup I - $500
To make special arrangements for purchasing reports, such as multiple copies for employees of your company, please e-mail Kelly Close
There are no refunds available for newsletter or reports from Close Concerns.
Read our new white paper - "Treating the Diabetes Infrastructure"
welcome!
New to Close Concerns?
Subscribe
Already registered?
Log in
WHAT WE DO
consulting
strategic advice and comprehensive information for those interested in the diabetes industry
diabetes close up
our monthly newsletter
industry reports
periodically we take the long view on trends or on specific breakthroughs.
TEAM
reports
Close Concerns is pleased to announce DIABETES ROUNDUP III, a unique 200-page compilation of cogent observations on the diabetes and obesity industries facing the industry today - a followup to our Diabetes Round Up I, published in 2004, and Diabetes Round Up II, published in 2006. Diabetes Round Up III features:
- Detailed financial models for the $20 billion diabetes drug market, the $8 billion blood glucose monitoring market, and $1-plus billion insulin pump market
- An in-depth drug pipeline database of 100-plus companies developing over 350 diabetes and obesity therapies (up from 50-plus companies developing over 200 therapies in 2006!)
- Top highlights of the top 10 academic diabetes conferences over the last two years (ADA, ADA Postgraduate Sessions, AADE, AACE, EASD, IDF, the Obesity Society, and others)
- Additional on fifty additional conferences of note (Canadian Diabetes Association; 2nd International Conference on Pre-Diabetes and the Metabolic Syndrome; AIDPIT: Artificial Insulin Delivery Systems, Pancreas, and Islet Transplantation, among others)
- Our selection of the top 25 diabetes-related articles in medical journals over the last year (JAMA, NEJM, Diabetes Care, The Lancet) and detailed reviews of each
- Our reports on over a dozen major analyst meetings over the last year (Amylin, BMS, Eli Lilly, Medtronic, Merck, Novo Nordisk, Orexigen, OSI Pharmaceuticals, Roche, Pfizer, Sanofi, Vivus)
- A detailed calendar of over 30 important upcoming diabetes meetings in 2009 and over a dozen (and growing) in 2010
- The Close Concerns High Five Awards: our assessment of five top diabetes product introductions over the past two years
- Every order comes with a ZIP drive of full detailed notes on each of the 50 conferences (over 2,000 pages in all)
Who will benefit?
- Professionals in business development, strategic planning, or marketing in companies with interests in diabetes or obesity. Diabetes Roundup II will broaden its readers understanding of what is happening across the medical technology, pharmaceutical, and biotech industries.
- Investors seeking a better understanding of the opportunities in diabetes and obesity.
Diabetes Roundup Testimonial:
- "Close Concerns is THE source for everything happening in diabetes. It keeps up on all the meetings, all the advances, and all the excitement in the field."
–Dr. Jay Skyler; Professor of Medicine, University of Miami Miller School of Medicine - "Close Concerns publications are the Gold Standard of what's happening in the world of diabetes. People wonder how I know so much about the business side of diabetes. My secret is now out: Diabetes Close Up."
–Dr. Irl B. Hirsh; Professor of Medicine, Washington University School of Medicine - "Diabetes Round Up is very thorough and is filled with extremely thoughtful insight. It definitely has its finger on the pulse in the diabetes world."
– Dr. Paul S. Jellinger; Past President of the American College of Endocrinology (ACE)